ArticleJACC. CardioOncology2023
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients: Systematic Review and Meta-Analysis.
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database.Journal of the National Cancer Institute · 2026Article
- Development and Validation of the Predicting Risk of Ischemic Stroke in Malignancy Estimation Tool.Journal of the American Heart Association · 2026Article
- Cardiac arrhythmias in cancer patients using the nationwide claim-based database in Japan.Journal of arrhythmia · 2025Article
- Risk Factors for Arterial Thromboembolic Events in Male Germ Cell Tumors Treated with Chemotherapy.Cancers · 2025Article
- Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders.Hematology reports · 2025Review
- Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study.Cancer medicine · 2025Article
- Construction of diagnostic models with machine-learning algorithms for colorectal cancer based on clinical laboratory parameters.Journal of gastrointestinal oncology · 2024Article
- Arterial Thrombosis in Patients with Cancer.Cancers · 2024Review
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- Anticoagulation and Arterial Thrombotic Events in Ambulatory Patients With Cancer: A Bayesian Re-Analysis and Perspective.JACC. CardioOncology · 2023Article
- To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy.JACC. CardioOncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk of arterial thrombotic events (ATEs) is high among patients on systemic anticancer therapies. Despite the efficacy of anticoagulants in the prevention of cancer-associated venous thromboembolism, it is unknown whether anticoagulation is effective to prevent ATEs. Objectives: This study sought to examine the efficacy and safety of anticoagulants in ATE prevention among ambulatory cancer patients. Methods: We performed a systematic review using Medline, Embase, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to May 21, 2022, and included studies comparing oral or parenteral anticoagulation with no anticoagulation among ambulatory patients receiving systemic anticancer therapy with no other indication for anticoagulation. The primary outcome was ATE (myocardial infarction, ischemic stroke, intra-abdominal arterial embolism, or peripheral artery occlusion). The secondary outcomes were major and nonmajor bleeding and all-cause mortality. Results: Fourteen randomized trials involving low-molecular-weight heparins, direct oral anticoagulants, and warfarin were included. ATEs were captured as coefficacy endpoints or adverse events. Anticoagulant use was not associated with a reduction in ATEs compared with placebo or standard treatment (RR: 0.73, 95% CI: 0.50-1.04; Conclusions: Anticoagulants did not reduce ATE risk among ambulatory patients on systemic anticancer therapy and were associated with increased bleeding. Based on the current data, anticoagulants have a limited role in ATE prevention in this population as a whole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.